4 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
Follow NNC126-0083: new trials by email Literature Review of NNC126-0083 trials Research Report on NNC126-0083
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacodynamics of Long Acting Growth Hormone NNC126-0083, somatropin - Growth Hormone Disorder, Growth Hormone Deficiency in Children | Phase 2 | Completed | Novo Nordisk A/S | 31 | 2009-08-01 | 2017-02-08 |
| Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 NNC126-0083, placebo - Growth Hormone Disorder, Adult Growth Hormone Deficiency | Phase 2 | Completed | Novo Nordisk A/S | 33 | 2008-07-01 | 2017-02-08 |
| Dose Study in Healthy Japanese Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 NNC126-0083, placebo - Growth Hormone Disorder, Healthy | Phase 1 | Completed | Novo Nordisk A/S | 40 | 2008-07-01 | 2017-02-08 |
| Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx® NNC126-0083, Norditropin® SimpleXx®, placebo - Growth Hormone Disorder, Healthy | Phase 1 | Completed | Novo Nordisk A/S | 56 | 2007-08-01 | 2017-02-09 |
Novo Nordisk A/S (4)
Denmark (3) · Belgium (1) · Czechia (1) · France (1) · Germany (1) · Israel (1) · North Macedonia (1) · Slovenia (1) · Spain (1) · Turkey (Türkiye) (1) · United Kingdom (1)
PMID 20427496, PMID 20718773, PMID 21177789, PMID 21724838, PMID 33864240
2008 (3)